IVA Inventiva SA
Financings ·
Inventiva reported preliminary first-half 2026 figures showing €166.1 million in cash and €67.8 million in short-term deposits. The company says current cash does not cover operations for the next 12 months.
We have not published a story on Inventiva SA yet. When there is news, it will appear here.
Inventiva S.A. is a clinical-stage biopharmaceutical company developing oral small molecule therapies for metabolic dysfunction-associated steatohepatitis, or MASH. It has a wholly-owned research and development facility and expertise in compounds that target nuclear receptors, transcription factors and epigenetic modulation. In February 2025 the company decided to focus exclusively on lanifibranor, and it discontinued research on its other pre-clinical programs, including YAP-TEAD and NR4A1, since June 2025. Lanifibranor is an orally available small molecule that activates all three peroxisome proliferator-activated receptor isoforms, which the company says can produce anti-fibrotic, anti-inflammatory and beneficial vascular and metabolic effects. The NATIVE Phase 2b trial met its primary endpoint at a dose of 1,200 mg after 24 weeks, and the FDA granted lanifibranor Breakthrough Therapy Designation for MASH in October 2020. The Phase 3 NATiV3 trial began in September 2021, with topline results targeted for the fourth quarter of 2026. If the results are positive, the company targets a new drug application in the first half of 2027, with potential commercialization in 2028. The company describes MASH as a progressive, chronic liver disease that affects 2-6% of the United States adult population.
| Product or program | What it is | Stage |
|---|---|---|
| Lanifibranor | Oral small molecule for MASH, the company's only product candidate in development | Phase 3 NATiV3 trial; topline results targeted for the fourth quarter of 2026 |
| Line | FY2024 | FY2023 |
|---|---|---|
| Revenue | €9.2 million | €17.5 million |
| Research and development | €90.9 million | €110.0 million |
| Cash from operations | -€85.9 million | -€81.6 million |
| Cash and equivalents | €96.6 million | €26.9 million |
Inventiva SA trades under the ticker IVA on EURONEXT.
Inventiva SA is listed on EURONEXT. Our directory also records these other listings: DUS:6IV; FWB:6IV; GETTEX:6IV; HAM:6IV; HAN:6IV; LS:A2DLV9; LSE:0RNK; LSX:A2DLV9; MUN:6IV; NASDAQ:IVA; OTC:IVEVF; SWB:6IV; TRADEGATE:6IV; XETR:6IV.
The SEC Central Index Key (CIK) for Inventiva SA is 1756594. Its filings are on SEC EDGAR.
193,236,978 shares as of 2025-12-31, per the cover page of its 20-F filed 2026-04-08.
Our directory records Inventiva SA under France.
Our directory classifies Inventiva SA as: Biotechnology. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Inventiva SA is FR0013233012.
aibio.space lists Inventiva SA among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as I0.
Inventiva S.A. is a clinical-stage biopharmaceutical company developing oral small molecule therapies for metabolic dysfunction-associated steatohepatitis, or MASH. It has a wholly-owned research and development facility and expertise in compounds that target nuclear receptors, transcription factors and epigenetic modulation.
Lanifibranor: Oral small molecule for MASH, the company's only product candidate in development Stage: Phase 3 NATiV3 trial; topline results targeted for the fourth quarter of 2026.
Our latest story on Inventiva SA, dated Jul 29, 2026: "Inventiva says cash covers operations to end of Q2 2027 after June financings". Inventiva reported preliminary first-half 2026 figures showing €166.1 million in cash and €67.8 million in short-term deposits. The company says current cash does not cover operations for the next 12 months. Source.
Our latest financing story, dated Jul 29, 2026: "Inventiva says cash covers operations to end of Q2 2027 after June financings". Inventiva reported preliminary first-half 2026 figures showing €166.1 million in cash and €67.8 million in short-term deposits. The company says current cash does not cover operations for the next 12 months. Source.
From our story of Jul 29, 2026: It says that without additional capital the company may be required to curtail, delay or discontinue programs, and that it may be unable to continue as a going concern. Source.
SEC records list Inventiva SA's filer category as: Accelerated filer.
Reported a financing. SEC Form 6-K. Source
Reported a financing. SEC Form F-3ASR. Source
Reported a financing. SEC Form 6-K. Source
Reported a financing. SEC Form 6-K. Source
Reported a financing. SEC Form 6-K. Source
Reported a financing. SEC Form 6-K. Source
Reported a financing. SEC Form 424B5. Source
Reported a financing. SEC Form F-3. Source
Reported a financing. SEC Form 6-K. Source
Reported a financing. SEC Form 6-K. Source
Reported a financing. SEC Form 6-K. Source
Reported a financing. SEC Form 6-K. Source
Reported a financing. SEC Form 6-K. Source
Reported a financing. SEC Form 6-K. Source
Reported a financing. SEC Form 6-K. Source
Reported a financing. SEC Form 6-K. Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio